How do you factor safety into treating patients with CRSwNP?

Sinus surgery is a pillar of CRS with nasal polyps treatment, but how do the safety risks compare to those of biologic therapy? Experts in the field explain how they identify which patients are better suited for Dupixent than surgery and why “none of us should feel threatened by the option of a nonsurgical treatment” like Dupixent.^1-3

While sinus surgery is associated with serious safety risks, Dupixent has a favorable safety profile across multiple indications and real-world use in [>500,000] patients.^1-3,a

References

Hosemann W, Draf C. Danger points, complications and medico-legal aspects in endoscopic sinus surgery. GMS Curr Top Otorhinolaryngol Head Neck Surg. 2013;12:Doc06. doi:10.3205/cto000098
Stankiewicz JA, Lal D, Connor M, Welch K. Complications in endoscopic sinus surgery for chronic rhinosinusitis: a 25-year experience. Laryngoscope. 2011;121(12):2684-2701. doi:10.1002/lary.21446 3. DUPIXENT Summary of Product Characteristics, 2022.

Hear From An Expert On Identify Patients Who Are Appropriate Candidates For Biologic Treatment

On average the typical patients with nasal polyps have had +1 sinus surgery, sinus surgery dose not cure the nasal polyps. A medication where i can prevent revision sinus surgery...a good thing for me and for the patient.

Read article

Hear From An Expert On The Type 2 Immune Response And Inflammation

Read article

Nasal Polyps

Hear from an expert on what does Dupixent bring to your practice?

Read article

MAT-BH-2201030/V1/FEB2023